PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients
42% change in treatment recommendations when using DCISionRT
News provided by
Share this article
Share this article
LAGUNA HILLS, Calif., April 21, 2021 /PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced results for a prospective study in 44 U.S. academic and community cancer centers that evaluated the impact of DCISionRT on clinicians recommendations to administer or omit adjuvant radiotherapy (RT) in patients with DCIS (ductal carcinoma in situ) following breast conserving surgery (BCS). Data published today in the
PreludeDx PREDICT Study Demonstrates High Clinical Utility of DCISionRT for DCIS Breast Cancer Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Cutting-edge life science company offers high upside cannabis medical product potential. The company aims to disrupt the drug development market by developing evidence-based cannabis products to help combat serious medical conditions
FREE
Only logged in users are allowed to post comments. Register/ Log in
The Market Oracle is a FREE Financial Markets Forecasting & Analysis web-site.
(c) 2005-2021 MarketOracle.co.uk (Market Oracle Ltd) - Market Oracle Ltd asserts copyright on all articles authored by our editorial team and all comments posted.
Any and all information provided within the web-site, is for general information purposes only and Market Oracle Ltd do not warrant the accuracy, timeliness or suitability of any information provided on this site. nor is or shall be deemed to constitute, financial or any other advice or recommendation by us. and are also not meant to be investment advice or solicitation or recommendation to establish market positions. We do not give investment advice and our comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to enter into a market position either stock, option, futures contract, bonds, commodity or any
The Next Marijuana Boom Could Be Even Bigger Than The Last
Published: January 18, 2021
That’s because, despite “Big Pharma’s” massive resources and staggering amounts of spending,
no large pharmaceutical company has ever been able to solve the industry’s most critical problem.
Drug development for major pharmaceutical companies can take as long as a decade.and cost hundreds of billions of dollars in research and development.
Yet a small, little-known company – which could become a truly disruptive cannabis player – now appears uniquely positioned to
upend the drug development market by developing evidence-based cannabis products to combat many of the world’s most serious medical conditions.